Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can AI read heart ultrasounds as well as trained sonographers?

NCT ID NCT07021599

Diagnosis Sponsor: Prince of Wales Hospital, Shatin, Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers are testing whether an artificial intelligence system can analyze echocardiogram images and draft reports as accurately as experienced sonographers in patients with heart failure. The trial enrolls adults with new or worsening heart failure symptoms and elevated heart failure blood markers. Participants are randomly assigned to have their heart ultrasound analyzed by either the AI system or a sonographer, with an experienced cardiologist reviewing all results. The main question is whether the AI's grading of heart function and valve problems matches the cardiologist's assessment, and whether AI saves time in producing reports.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an artificial intelligence system that analyzes and drafts reports from echocardiogram images
What this could lead to
If AI readings match expert cardiologists, hospitals could speed up heart failure diagnosis and free sonographers to scan more patients.
What could go wrong
AI may miss subtle heart abnormalities that trained sonographers catch, and the trial measures agreement with expert readings rather than whether patients do better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 514 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or above * Has new or worsening of heart failure symptoms * Elevated heart failure blood markers (N-terminal prohormone of brain natriuretic peptide, "NTproBNP") within 3 months from enrolment or by point-of-care blood test, to ensure that the patient's symptoms are cardiac origin * Provision of written informed consent Exclusion Criteria: * Known severe valvular heart disease * Prior prosthetic valve implantation * Previously known or suspected \>=severe tricuspid regurgitation, \>=moderate aortic regurgitation, \>=moderate mitral stenosis or pericardial disease during detected during image acquisition * Insufficient image quality for proper analysis determined by the scanning sonographer (estimated to be 15% of all echocardiograms screened)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • Prince of Wales Hospital

    Hong Kong, Shatin, 0000, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.